Jpmorgan Chase & CO Crinetics Pharmaceuticals, Inc. Transaction History

Jpmorgan Chase & CO

$1.1 Trillion
Q1 2024

A detailed history of Jpmorgan Chase & CO transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 375,986 shares of CRNX stock, worth $16.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

375,986

Previous 93,104 303.83%

Holding current value

$16.8 Million

Previous $3.31 Million 431.37%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$34.76 - $46.81 $9.83 Million - $13.2 Million	282,882 Added 303.83%	375,986 $17.6 Million
Q4 2023 Feb 12, 2024	BUY	$25.62 - $37.07 $990,827 - $1.43 Million	38,674 Added 71.05%	93,104 $3.31 Million
Q3 2023 Nov 14, 2023	BUY	$15.97 - $30.59 $171,773 - $329,026	10,756 Added 24.63%	54,430 $1.62 Million
Q2 2023 Aug 11, 2023	BUY	$15.73 - $23.6 $49,722 - $74,599	3,161 Added 7.8%	43,674 $787,000
Q1 2023 May 18, 2023	BUY	$15.31 - $21.1 $617,192 - $850,604	40,313 Added 20156.5%	40,513 $650,000

Q1 2023 May 11, 2023	SELL	$15.31 - $21.1 $528,103 - $727,823	-34,494 Reduced 99.42%	200 $3,000
Q4 2022 Feb 13, 2023	BUY	$15.49 - $19.05 $31,041 - $38,176	2,004 Added 6.13%	34,694 $636,000
Q3 2022 Nov 14, 2022	BUY	$18.11 - $22.37 $32,616 - $40,288	1,801 Added 5.83%	32,690 $642,000
Q2 2022 Aug 11, 2022	SELL	$16.49 - $27.64 $838,467 - $1.41 Million	-50,847 Reduced 62.21%	30,889 $576,000
Q1 2022 May 11, 2022	BUY	$17.15 - $28.31 $573,890 - $947,337	33,463 Added 69.32%	81,736 $1.79 Million
Q4 2021 Feb 10, 2022	BUY	$19.35 - $28.41 $487,871 - $716,301	25,213 Added 109.34%	48,273 $1.37 Million
Q3 2021 Nov 12, 2021	BUY	$16.88 - $25.23 $389,252 - $581,803	23,060 New	23,060 $486,000

Others Institutions Holding CRNX

# of Institutions

220

Shares Held

75.8M

Call Options Held

631K

Put Options Held

749K

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.41B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Crinetics Pharmaceuticals, Inc. Transaction History